Clinical trial · Observational
Immunohistochemical Expression of EGFR in the Patients Having Oral Squamous Cell Carcinoma
Immunohistochemical Expression of EGFR in Oral Squamous Cell Carcinoma- A Cross Sectional Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Oral squamous cell carcinoma (OSCC) is one of the top 10 most common malignancies worldwide. Oral squamous cell carcinoma forms a major health problem in many countries. The reason for the high incidence of oral cavity cancers in Pakistan, and South Asia in general, is the frequent, persistent, and prevalent use of substances classified as oral cancer risk factors. These include betel quid, areca nut, smoking, smokeless tobacco, viral infections such as EBV, HPV, poor oral hygiene (including sharp teeth and decay), ultraviolet (UV) exposure, nutrition, and genetic predisposition. For several decades the management of OSCC consisted of surgery with or without radiotherapy or chemoradiotherapy. Associated with worse prognosis, overexpression of EGFR may lead to invasion, cellular migration, enhanced angiogenesis, decreased cell apoptosis, and increased metastatic potential. However, advances in immunotherapy have had a major impact on cancer treatment. This study was exclusively designed to highlight the immunohistochemical detection of expression pattern of EGFR in already diagnosed cases of lip and OSCC in histopathology dept of AFIP and its correlation with the grade of the tumor. In this study, contact details of all diagnosed cases of SCC of lips and oral cavity from June to November 2023 were taken from the archives of Histopathology department. The patients were contacted for consent approval for participation. The data was collected (as per proforma attached), including demographic details, location of tumor. Blocks were retrieved, grade of tumor was identified followed by the application of EGFR marker. Patterns of expression of EGFR were evaluated and compared with grade of tumor to strengthen the correlation of this association.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer | Malignant Lip and Oral Cavity Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BioSB EGFR antibody | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Different Grades of squamous cell carcinoma
- description
- Diagnostic test: Biopsy specimens Fresh sections from formalin fixed and paraffin embedded block with sections from the tumor will be prepared followed by Hematoxylin and Eosin staining according to the standard protocol.
- interventionNames
- Diagnostic Test: BioSB EGFR antibody
Primary outcomes (1)
- measure
- Correlation of EGFR expression with tumor
- timeFrame
- 05 months
- description
- To determine the correlation of EGFR with tumor and to establish EGFR as a prognostic marker
Secondary outcomes (1)
- measure
- Association of EGFR expression with tumor
- timeFrame
- 05 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Cases of surgically treated lip/oral cavity squamous cell carcinoma * Patients of all age groups, irrespective of their gender * Patients with a tumor located in the tongue, inferior and superior gingivae, buccal mucosa, floor of the mouth, palate, alveolus and vestibule(buccal/labial and mandible/maxilla) Exclusion Criteria: * All specimens with inadequate or poor fixation. * All specimen of patients having received chemotherapy/radiotherapy prior to surgery * Very scanty tissue biopsies or those with extensive tissue necrosis * Patients not consenting to be the part of the study
References
Publications (3)
- BACKGROUNDHashmi AA, Bukhari U, Aslam M, Joiya RS, Kumar R, Malik UA, Zia S, Khan AR, Saleem M, Irfan M. Clinicopathological Parameters and Biomarker Profile in a Cohort of Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). Cureus. 2023 Jul 15;15(7):e41941. doi: 10.7759/cureus.41941. eCollection 2023 Jul. PMID 37588336
- BACKGROUNDGupta S, Pandey P, Verma S, Verma A. p16, p53 and EGFR expression in head and neck squamous cell carcinoma and their correlation with clinicopathological parameters. J Cancer Res Ther. 2024 Apr 1;20(3):881-887. doi: 10.4103/jcrt.JCRT_201_20. Epub 2024 Jun 27. PMID 39023595
- BACKGROUNDBernardes VF, Gleber-Netto FO, Sousa SF, Rocha RM, Aguiar MC. EGFR status in oral squamous cell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series study. BMJ Open. 2013 Jan 28;3(1):e002077. doi: 10.1136/bmjopen-2012-002077. PMID 23358562